Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 55 to 90 years of age, inclusive, at the time of informed consent.~* Subjects who are residing at their current location for at least 14 days before screening and are expected to remain at the same location for the duration of the trial.~* Subjects with diagnosis of probable Alzheimer's disease according to NINCDS-ADRDA criteria.~* Subjects with a MMSE score of 5 to 22, inclusive, at screening and baseline visits.~* Subjects with onset of symptoms of agitation at least 2 weeks prior to the screening visit.~* Subjects with a total score greater than or equal to 4 on the agitation aggression item of the NPI-NH or NPI/NPI-NH at the screening and baseline visits.~* Subjects who require pharmacotherapy for the treatment of agitation per the investigator's judgement, after an evaluation of reversible factors (eg, pain, infection, polypharmacy) and a trial of nonpharmacological interventions.~* Subjects must have a previous MRI or CT scan of the brain, which was performed after the onset of symptoms of dementia, with findings consistent with the diagnosis of Alzheimer's disease.~Exclusion Criteria:~* Subjects with dementia or other memory impairment not due to Alzheimer's disease.~* Subjects with history of stroke, well-documented transient ischemic attack, or pulmonary or cerebral embolism.~* Subjects who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal, or psychiatric disorders.~* Subjects who have been diagnosed with an Axis I disorder (DSM-IV-TR criteria).~* Subjects with uncontrolled hypertension.~* Subjects with uncontrolled insulin-dependent diabetes mellitus (IDDM)~* Subjects with epilepsy or a history of seizures.~* Subjects considered in poor general health based on the investigator's judgment.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo Once-Daily
- Brexpiprazole (flexible dose range 0.5 to 2 mg) (Type: EXPERIMENTAL): Titrate up from 0.25 mg/day brexpiprazole to 1 mg/day brexpiprazole. After achieving 1 mg/day target dose may be increased or decreased based on efficacy and tolerability. Allowable flexible doses will be 0.5 mg/day, 1 mg/day, or 2 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).